Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
There are several factors to consider; see below to understand more.
Persistent symptoms despite optimized mesalamine and steroids may reflect inadequate rectal drug reach, undertreatment or adherence issues, steroid dependence, disease extension, or infection, and next steps include objective reassessment plus escalation to advanced therapies such as biologics (anti-TNF, vedolizumab, ustekinumab), oral small molecules (JAK inhibitors, ozanimod), and consideration of investigational options or clinical trials.
If you're still dealing with rectal bleeding, urgency, mucus, or abdominal discomfort despite treatment, you're not alone. Proctosigmoiditis — a form of ulcerative colitis (UC) affecting the rectum and sigmoid colon — can sometimes become refractory, meaning it doesn't respond adequately to standard therapies.
This can be frustrating and discouraging. But refractory disease does not mean untreatable. It means it's time to reassess and consider new strategies — including investigational drugs for refractory proctosigmoiditis and advanced therapies.
Let's walk through why this happens and what medical next steps may help.
In medical terms, "refractory" usually means:
For proctosigmoiditis, first-line treatments typically include:
If these fail, your condition may be classified as steroid-dependent or steroid-refractory, which requires escalation of therapy.
There are several common reasons treatment may not be working:
Rectal therapies must physically reach inflamed tissue.
If inflammation extends farther than expected, therapy may not be reaching the full area.
Low doses or inconsistent use of medications can limit effectiveness. Adherence matters — especially with rectal therapies.
If symptoms return as soon as steroids are tapered, the immune response is still active and requires a more targeted long-term solution.
Occasionally:
Repeat evaluation may be necessary.
If you've failed optimized mesalamine and steroid therapy, guidelines from major gastroenterology societies recommend moving to advanced immune-targeting therapies.
These include:
Escalation is not a failure — it's simply the next appropriate medical step.
Here's what your gastroenterologist may discuss.
Biologics target specific immune pathways that drive inflammation.
These block tumor necrosis factor (TNF), a key inflammatory protein.
Pros:
Considerations:
Vedolizumab works primarily in the gut, limiting systemic immune suppression.
Pros:
Ustekinumab targets interleukin pathways involved in inflammation.
Pros:
These are newer and increasingly used for refractory cases.
They block Janus kinase pathways that promote inflammation.
Advantages:
Risks:
Helps reduce immune cell migration to the gut.
Benefits:
Clinical research is expanding rapidly. Investigational drugs for refractory proctosigmoiditis focus on:
Examples of emerging targets include:
Clinical trials may offer access to these therapies before full approval. If standard treatments have failed, asking your gastroenterologist about clinical trial eligibility may be reasonable.
Before moving to advanced therapy, your doctor may:
This ensures the right therapy is chosen.
Medication is critical — but it's not the only factor.
Consider:
Diet alone cannot cure refractory proctosigmoiditis, but symptom management strategies can reduce flare burden.
For severe, persistent disease that does not respond to multiple advanced therapies, colectomy (removal of the colon) may be discussed.
This is typically reserved for:
While surgery can be life-changing, it is generally considered only after exhausting medical options.
Sometimes symptoms persist even when inflammation is controlled. This may reflect:
Objective testing helps differentiate active inflammation from functional symptoms.
If you're unsure whether your current symptoms indicate active inflammation or something else, using a free Ulcerative Colitis symptom checker can help you identify patterns and prepare informed questions for your next gastroenterology appointment.
Seek immediate medical attention if you experience:
These may signal a serious complication requiring urgent evaluation.
Always speak to a doctor promptly if symptoms feel severe, rapidly worsening, or concerning.
If your proctosigmoiditis remains refractory, consider discussing:
Refractory proctosigmoiditis is challenging — but it is not hopeless.
The treatment landscape for ulcerative colitis has changed dramatically in the past decade. Multiple biologics, small molecules, and investigational drugs for refractory proctosigmoiditis are expanding the options available.
If your current plan is not working:
Most importantly, do not manage this alone. Persistent inflammation can lead to complications if untreated. Speak openly with your gastroenterologist about your ongoing symptoms and concerns.
Effective control is possible — but it may require a new approach.
(References)
* Al-Brahim T, Al-Nassar M, Alfadhli A, Al-Otaibi S, Al-Fadhli B, Al-Hussaini A, Al-Bahar F, Akbar M, Al-Attar K, Al-Taiar A. Vedolizumab in ulcerative proctosigmoiditis refractory to anti-TNF therapy: a single-center experience. World J Gastroenterol. 2018 Jul 7;24(25):2796-2802. doi: 10.3748/wjg.v24.i25.2796. PMID: 30018485; PMCID: PMC6035978.
* Söderholm JD, Olén O, Sjöberg D. Mechanisms of therapy failure in inflammatory bowel disease. Frontline Gastroenterol. 2019 Apr;10(2):123-128. doi: 10.1136/flgastro-2018-101140. Epub 2019 Jan 10. PMID: 30976315; PMCID: PMC6443424.
* Ko HM, Kim HS, Lee HS, Lee HJ, Lee SY, Jeon SR, Park YS, Kim YS, Chung SY, Choi CH, Eun CS, Han DS, Kim TJ. New therapeutic options for ulcerative colitis: an update. Int J Colorectal Dis. 2020 Jan;35(1):1-16. doi: 10.1007/s00384-019-03460-2. Epub 2019 Nov 16. PMID: 31734685.
* Olén O, Sjöberg D, Söderholm JD. Management of inflammatory bowel disease: current and future therapies. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):15-32. doi: 10.1038/s41575-020-00366-0. Epub 2020 Oct 8. PMID: 33029015.
* Lamb CA, Lim AG, Lindsay JO, Mansfield JC, Irving PM, Smith PJ, Srivastava A, Saxena S, Hart AL, Goodhand JR. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022 Feb 10;16(2):167-184. doi: 10.1093/ecco-jcc/jjab178. PMID: 34160424.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.